Search

Author/Creator Vincent, Michael S

1. Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis. Issue 3 (24th August 2021)

Authors:
Hassan-Zahraee, Mina; Ye, Zhan; Xi, Li; Baniecki, Mary Lynn; Li, Xingpeng; Hyde, Craig L; Zhang, Jenny; Raha, Nancy; Karlsson, Fridrik; Quan, Jie; Ziemek, Daniel; Neelakantan, Srividya; Lepsy, Christopher; Allegretti, Jessica R; Romatowski, Jacek; Scherl, Ellen J; Klopocka, Maria; Danese, Silvio;...
Journal:
Inflammatory bowel diseases
Issue:
Volume 28:Issue 3(2022)
Page Start:
434
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis. Issue 3 (2nd March 2022)

Authors:
Hassan-Zahraee, Mina; Ye, Zhan; Xi, Li; Baniecki, Mary Lynn; Li, Xingpeng; Hyde, Craig L; Zhang, Jenny; Raha, Nancy; Karlsson, Fridrik; Quan, Jie; Ziemek, Daniel; Neelakantan, Srividya; Lepsy, Christopher; Allegretti, Jessica R; Romatowski, Jacek; Scherl, Ellen J; Klopocka, Maria; Danese, Silvio;...
Journal:
Inflammatory bowel diseases
Issue:
Volume 28:Issue 3(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Issue 3 (26th September 2016)

Authors:
Wallace, Daniel J; Strand, Vibeke; Merrill, Joan T; Popa, Serghei; Spindler, Alberto J; Eimon, Alicia; Petri, Michelle; Smolen, Josef S; Wajdula, Joseph; Christensen, Jared; Li, Cheryl; Diehl, Annette; Vincent, Michael S; Beebe, Jean; Healey, Paul; Sridharan, Sudhakar
Journal:
Annals of the rheumatic diseases
Issue:
Volume 76:Issue 3(2017)
Page Start:
534
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study. (March 2021)

Authors:
Tehlirian, Christopher; Peeva, Elena; Kieras, Elizabeth; Scaramozza, Matthew; Roberts, Erika S; Singh, Ravi Shankar P; Pradhan, Vivek; Banerjee, Anindita; Garcet, Sandra; Xi, Li; Gale, Jeremy D; Vincent, Michael S; Krueger, James
Journal:
Lancet
Issue:
Volume 3:Number 3(2021)
Page Start:
e204
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗